Clinical Trial Update: A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of two doses of topiramate as monotherapy in patients with newly diagnosed or recurrent epilepsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Topiramate (Topiramate)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Epilepsy, Seizures | Phase 3 | Status: COMPLETED